STTKShattuck Labs, Inc.

Nasdaq shattucklabs.com


$ 7.65 $ -0.09 (-1.17 %)    

Wednesday, 22-May-2024 15:59:50 EDT
QQQ $ 454.82 $ -0.09 (-0.02 %)
DIA $ 398.57 $ -2.12 (-0.53 %)
SPY $ 530.36 $ -1.53 (-0.29 %)
TLT $ 91.26 $ 0.11 (0.12 %)
GLD $ 225.37 $ -4.12 (-1.84 %)
$ 7.63
$ 7.65
$ 0.00 x 0
$ 0.00 x 0
$ 7.52 - $ 7.77
$ 1.33 - $ 11.76
202,582
na
385.82M
$ 0.93
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 02-29-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 02-23-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-15-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
14 03-16-2021 12-31-2020 10-K
15 11-13-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-shattuck-labs-maintains-28-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Shattuck Labs (NASDAQ:STTK) with a Buy and maintains $28 price t...

 needham-reiterates-buy-on-shattuck-labs-maintains-12-price-target

Needham analyst Gil Blum reiterates Shattuck Labs (NASDAQ:STTK) with a Buy and maintains $12 price target.

 needham-reiterates-buy-on-shattuck-labs-maintains-12-price-target

Needham analyst Gil Blum reiterates Shattuck Labs (NASDAQ:STTK) with a Buy and maintains $12 price target.

 hc-wainwright--co-reiterates-buy-on-shattuck-labs-maintains-28-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Shattuck Labs (NASDAQ:STTK) with a Buy and maintains $28 price t...

 shattuck-labs-q1-2024-gaap-eps-037-beats-046-estimate-sales-1115m-beat-228500k-estimate

Shattuck Labs (NASDAQ:STTK) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.46)...

 shattuck-labs-reports-preclinical-data-demonstrating-therapeutic-utility-of-trim7-inhibition-to-prevent-or-reverse-acquired-resistance-to-immune-checkpoint-therapy

These data were featured in an oral presentation during the AACR Annual Meeting 2024, being held from April 5-10, 2024, in San ...

 needham-reiterates-buy-on-shattuck-labs-maintains-12-price-target

Needham analyst Gil Blum reiterates Shattuck Labs (NASDAQ:STTK) with a Buy and maintains $12 price target.

 needham-reiterates-buy-on-shattuck-labs-maintains-12-price-target

Needham analyst Gil Blum reiterates Shattuck Labs (NASDAQ:STTK) with a Buy and maintains $12 price target.

 hc-wainwright--co-reiterates-buy-on-shattuck-labs-maintains-28-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Shattuck Labs (NASDAQ:STTK) with a Buy and maintains $28 price t...

 shattuck-labs-q4-eps-041-beats-057-estimate

Shattuck Labs (NASDAQ:STTK) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.57)...

 hc-wainwright--co-reiterates-buy-on-shattuck-labs-maintains-28-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Shattuck Labs (NASDAQ:STTK) with a Buy and maintains $28 price t...

 needham-reiterates-buy-on-shattuck-labs-maintains-12-price-target

Needham analyst Gil Blum reiterates Shattuck Labs (NASDAQ:STTK) with a Buy and maintains $12 price target.

 why-rxsight-shares-are-trading-higher-by-20-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24...

 shattuck-labs-announces-50m-public-offering-of-common-stock-and-concurrent-private-placement-of-pre-funded-warrants

Shattuck Labs, Inc. ("Shattuck" or the "company") (NASDAQ:STTK), a clinical-stage biotechnology company pioneer...

 why-nxu-shares-are-trading-higher-by-around-42-here-are-20-stocks-moving-premarket

Shares of Nxu, Inc. (NASDAQ: NXU) rose sharply in pre-market trading after the company signed a letter of intent outlining inv...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION